Drugs / CKD-391
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05634447 | Dec 2022 → Feb 2023 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04354987 | Oct 2019 → Jan 2020 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03793985 | Sep → Oct 2018 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02501200 | Aug → Dec 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02461004 | Jul → Oct 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-391 | “CKD-391 40/10mg” NCT03793985 ↗ |
| Route | Oral | “CKD-391 - A single oral dose of 1 tablet under fasting condition” NCT05634447 ↗ |